Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The objective of this study is to investigate the safety and efficacy of administering 372.6 mg of AK1820 (isavuconazonium sulfate) intravenously or orally to adult Japanese patients with deep mycosis. The primary endpoint is safety (percentage of patients with adverse events after starting the study treatment).
Epistemonikos ID: eae4a6c26b86385e3ff8abf5e9ab109cab54ca91
First added on: May 21, 2024